Sarilumab Subcutaneous and Hyperlipidemia
Result of checking the interaction of drug Sarilumab Subcutaneous and disease Hyperlipidemia for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of sarilumab is associate with increases in lipid parameters such as LDL cholesterol, HDL cholesterol and/or triglycerides. Care should be exercised when using this agent in patients with lipid abnormalities. It is recommended to assess lipid parameters at baseline and parameters approximately 4 to 8 weeks following initiation of treatment, then at approximately 6 months intervals.
Generic Name: sarilumab
Brand Name: Kevzara, Kevzara Pre-filled Pen
Synonyms: Sarilumab